Evinacumab(TD-HV176016) is a research-grade recombinant antibody targetingANG-5. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.
Species reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species
Human
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
ANG-5, Angiopoietin-like protein 3, ANGPT5, Angiopoietin-5, ANGPTL3, Angiopoietin-related protein 3
Endotoxin level
Please contact the lab for this information.
Purity
>95% purity as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9Y5C1
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names
REGN1500, 1446419-85-7
Background
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia.
Caption
SEC-HPLC detection for Research Grade Evinacumab. | Detects Human ANGPTL3 in direct ELISAs. | SDS-PAGE for Research Grade Evinacumab
Note
For research use only. Not suitable for clinical or therapeutic use.